Generic name: melphalan flufenamide
Dosage form: lyophilized powder for injection
Drug class:Alkylating agents
The Pepaxto brand name has been discontinued in the U.S. If generic versions of this product have been approved by the FDA, there may be generic equivalents available.
What is Pepaxto?
Pepaxto is a prescription medicine used in combination with the medicine dexamethasone to treat adults with multiple myeloma who did not respond to or stopped responding to at least four prior medicines including at least one proteasome inhibitor, one immunomodulatory agent and one
CD38-directed antibody.
Pepaxto is not for use to prepare for transplant.
It is not known if this medicine is safe and effective in children.
Who should not take Pepaxto?
Do not receive Pepaxto if you have a history of a severe allergic reaction to melphalan flufenamide or melphalan.
Before receiving Pepaxto
Before receiving Pepaxto, tell your healthcare provider about all of your medical conditions, including if you:
- have an infection
- are pregnant or plan to become pregnant. Pepaxto may harm your unborn baby.
Females who are able to become pregnant:- Your healthcare provider will check to see if you are pregnant before you start treatment.
- You should use an effective method of birth control (contraception) during treatment and for 6 months after the last dose.
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment.
Males with female partners who are able to become pregnant:
- You should use an effective method of birth control (contraception) during treatment and
